Showing results (411-420 of 423) with videos related to

Sort By:
Pageof 43
The Lancet. Neurology|August 10, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trialMichael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.
JAMA Neurology|November 23, 2020
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialBrian J Wainger, Eric A Macklin, Steve Vucic, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 24, 2020
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALSJeremy M Shefner, Jinsy A Andrews, Angela Genge, et al.
Neurology|February 18, 2021
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENTAnthony A Amato, Michael G Hanna, Pedro M Machado, et al.
The New England Journal of Medicine|September 3, 2020
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral SclerosisSabrina Paganoni, Eric A Macklin, Suzanne Hendrix, et al.
Indian Heart Journal|August 10, 2020
Cardiological society of India document on safety measure during echo evaluation of cardiovascular disease in the time of COVID-19Rakesh Gupta, Mrinal Kanti Das, P P Mohanan, et al.
Muscle & Nerve|October 16, 2020
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosisSabrina Paganoni, Suzanne Hendrix, Samuel P Dickson, et al.
JAMA|March 11, 2025
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, James D Berry, Nicholas J Maragakis, et al.
JAMA Neurology|March 11, 2025
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial, Jinsy Andrews, Sabrina Paganoni, et al.
JAMA|March 11, 2025
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial, Jeremy M Shefner, Björn Oskarsson, et al.
Pageof 43